ArticlePloS one2012
β-Cell regeneration mediated by human bone marrow mesenchymal stem cells.
Article in PloS one, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 59 citations in OpenAlex.
- Bone Marrow Mesenchymal Stromal Cells and Their Derived Extracellular Vesicles Protect Pancreatic Beta-TC-6 Cells From Hypoxia-Induced Injury via miR-539-3p-Mediated Downregulation of CD36 Expression.Stem cells international · 2026Article
- Stem cell therapy for diabetes: Advances, prospects, and challenges.World journal of diabetes · 2025Review
- Protective effect of mesenchymal stromal cells in diabetic nephropathy: the In vitro and In vivo role of the M-Sec-tunneling nanotubes.Clinical science (London, England : 1979) · 2024Article
- Human mesenchymal stem/stromal cell based-therapy in diabetes mellitus: experimental and clinical perspectives.Stem cell research & therapy · 2024Review
- A Supportive Role of Mesenchymal Stem Cells on Insulin-Producing Langerhans Islets with a Specific Emphasis on The Secretome.Biomedicines · 2023Review
- Novel insights regarding the role of noncoding RNAs in diabetes.World journal of diabetes · 2023Review
- Mesenchymal Stem Cells (MSCs): A Novel Therapy for Type 2 Diabetes.Stem cells international · 2022Review
- Diagnosis and treatment of type 1 diabetes at the dawn of the personalized medicine era.Journal of translational medicine · 2021Review
- Mesenchymal stem cells promote pancreatic β-cell regeneration through downregulation of FoxO1 pathway.Stem cell research & therapy · 2020Article
- BMSCs and miR-124a ameliorated diabetic nephropathy via inhibiting notch signalling pathway.Journal of cellular and molecular medicine · 2018Article
- Article
- Article
- Long term effect and safety of Wharton's jelly-derived mesenchymal stem cells on type 2 diabetes.Experimental and therapeutic medicine · 2016Article
- In vitro differentiation of human umbilical cord Wharton's jelly mesenchymal stromal cells to insulin producing clusters.World journal of clinical cases · 2015Article
- Therapeutic efficacy and biodistribution of allogeneic mesenchymal stem cells delivered by intrasplenic and intrapancreatic routes in streptozotocin-induced diabetic mice.Stem cell research & therapy · 2015Article
- Differentiation of Human Bone Marrow-Derived Mesenchymal Stem Cells into Insulin-Producing Cells: Evidence for Further Maturation In Vivo.BioMed research international · 2015Article
- Mesenchymal Stem Cells: Rising Concerns over Their Application in Treatment of Type One Diabetes Mellitus.Journal of diabetes research · 2015Review
- Different Tissue-Derived Stem Cells: A Comparison of Neural Differentiation Capability.PloS one · 2015Article
- Tissue engineering approaches to cell-based type 1 diabetes therapy.Tissue engineering. Part B, Reviews · 2014Review
- Human β-cell regeneration: progress, hurdles, and controversy.Current opinion in endocrinology, diabetes, and obesity · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bone marrow mesenchymal stem cells (BMSCs) have been shown to ameliorate diabetes in animal models. The mechanism, however, remains largely unknown. An unanswered question is whether BMSCs are able to differentiate into β-cells in vivo, or whether BMSCs are able to mediate recovery and/or regeneration of endogenous β-cells. Here we examined these questions by testing the ability of hBMSCs genetically modified to transiently express vascular endothelial growth factor (VEGF) or pancreatic-duodenal homeobox 1 (PDX1) to reverse diabetes and whether these cells were differentiated into β-cells or mediated recovery through alternative mechanisms. Human BMSCs expressing VEGF and PDX1 reversed hyperglycemia in more than half of the diabetic mice and induced overall improved survival and weight maintenance in all mice. Recovery was sustained only in the mice treated with hBMSCs-VEGF. However, de novo β-cell differentiation from human cells was observed in mice in both cases, treated with either hBMSCs-VEGF or hBMSCs- PDX1, confirmed by detectable level of serum human insulin. Sustained reversion of diabetes mediated by hBMSCs-VEGF was secondary to endogenous β-cell regeneration and correlated with activation of the insulin/IGF receptor signaling pathway involved in maintaining β-cell mass and function. Our study demonstrated the possible benefit of hBMSCs for the treatment of insulin-dependent diabetes and gives new insight into the mechanism of β-cell recovery after injury mediated by hBMSC therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.